medigraphic.com

2002, Número 2

<< Anterior Siguiente >>

Enf Infec Microbiol 2002; 22 (2)


Infecciones producidas por bacterias grampositivas. Controversias relacionadas al desarrollo de resistencia

Morfín OR, Rangel FS, Rodríguez NE

Idioma: Español
Referencias bibliográficas: 45
Paginas: 46-50
Archivo PDF: 48.77 Kb.


RESUMEN

El desarrollo de resistencia bacteriana a antimicrobianos es un problema mundial que amenaza la salud pública. En países como Estados Unidos de Norteamérica el 64% de las infecciones nosocomiales bacterianas son provocados por grampositivos y la resistencia a meticilina y vancomicina es elevada. Aunado a su gran capacidad de diseminación, estos patógenos tienen resistencia intrínseca a la gran mayoría de los antibióticos de uso clínico. Un problema actual es el desarrollo de resistencia de S. aureus a los glicopéptidos complicando notablemente la selección de la terapéutica adecuada contra estas bacterias emergentes. En estas circunstancias se debe escoger el antibiótico con mejor perfil de actividad, mejor farmacocinética y farmacodinamia constante y el más seguro. En el primer plano de este tipo de medicamentos están las oxazolidinonas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Edmond MB, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29(2):239-44.

  2. Kaye KS, Fraimow HS, Abrutyn E. Pathogens resistant to antimicrobial agents. Epidemiology, molecular mechanisms, and clinical management. Infect Dis Clin North Am 2000;14 (2): 293-319.

  3. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev 2000;13(4):686-707.

  4. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev 2000;13(4):686-707.

  5. Srinivasan A, Dick JD, Perl TM. Vancomycin resistance in staphylococci. Clin Microbiol Rev 2002;15(3):430-8.

  6. Edmond MB, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995;20(5):1126-33.

  7. Hiramatsu K, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother, 1997;40(1):135-6.

  8. Fridkin SK. Increasing prevalence of antimicrobial resistance in intensive care units. Crit Care Med 2001;29(4 Suppl):N64-8.

  9. Carmeli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg Infect Dis 2002;8(8):802-7.

  10. Sieradzki K, et al. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999;340(7):517-23.

  11. Fridkin SK, et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern Med 2001;135(3):175-83.

  12. Gonzalez C, et al. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999;29(5):1171-7.

  13. Burnie J, et al. Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to vancomycin. Clin Infect Dis 2000;31(3):684-9.

  14. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001;7(2):178-82.

  15. Appelbaum PC. Resistance among Streptococcus pneumoniae: Implications for drug selection. Clin Infect Dis 2002;34(12): 1613-20.

  16. Low DE, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother 2002;46(5):1295-301.

  17. Garrett DO, et al. The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. Infect Control Hosp Epidemiol 1999;20(3):167-70.

  18. Smith TL, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999;340(7):493-501.

  19. Hooper DC. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis 2002;2(9):530-8.

  20. Hussain FM, et al. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates. J Infect Dis 2002;186(5):661-7.

  21. Edmond MB, et al. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996;23(6):1234-9.

  22. Sieradzki K, et al. Heterogeneously vancomycin-resistant Staphylococcus epidermidis strain causing recurrent peritonitis in a dialysis patient during vancomycin therapy. J Clin Microbiol 1999;37(1):39-44.

  23. Paradisi F, Corti G, Messeri D. Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Med Clin North Am 2001;85(1):1-17.

  24. Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant Gram-positive bacterial infections. Clin Infect Dis, 2000;30(1):146-51.

  25. Rubinstein E, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001;32(3):402-12.

  26. Stevens DL, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34(11):1481-90.

  27. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996;22(5):387-94.

  28. Luna CM, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997;111(3):676-85.

  29. Rello J, et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997;156(1):196-200.

  30. Trouillet JL, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998;157(2):531-9.

  31. Ibrahim EH, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118(1):146-55.

  32. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000;31(Suppl 4):S131-8.

  33. Iregui M, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002;122(1):262-8.

  34. Leibovici L, et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998;244(5):379-86.

  35. Ena J, et al. The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study. Jama 1993;269(5): 598-602.

  36. Fridkin SK, et al. Determinants of vancomycin use in adult intensive care units in 41 United States hospitals. Clin Infect Dis 1999;28(5):1119-25.

  37. Daschner FD, et al. Pharmacokinetics of vancomycin in serum and tissue of patients undergoing open-heart surgery. J Antimicrob Chemother 1987;19(3):359-62.

  38. Lamer C, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993;37(2):281-6.

  39. Martin C, et al. Penetration of vancomycin into mediastinal and cardiac tissues in humans. Antimicrob Agents Chemother 1994;38(2):396-9.

  40. Cruciani M, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996;38(5):865-9.

  41. Lundstrom TS, Sobel JD. Antibiotics for Gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid. Infect Dis Clin North Am 2000;14(2):463-74.

  42. Ford CW, et al. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob Agents Chemother 1996;40(6): 1508-13.

  43. Shinabarger DL, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997;41(10):2132-6.

  44. Swaney SM, et al. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998;42(12):3251-5.

  45. Plouffe JF. Emerging therapies for serious Gram-positive bacterial infections: a focus on linezolid. Clin Infect Dis 2000;31 (Suppl 4):S144-9




2020     |     www.medigraphic.com